Map of spatial GPoE folds and predictive ability by fold. by Forrest Li (21512582)

“…<p>Correlations between genetics and environment are demonstrated through prediction but decrease when considering spatial distance. <b>A)</b> Map of sampled cross-validation folds used in spatial GPoE. …”

Coupled negative feedback decreases the overall LG. by Rong Gao (476219)

Illustrations of the SeqFold2D network and the Stralign dataset. by Xiangyun Qiu (316117)

Clinical characteristics of patients in the increased-, stable-, and decreased-RPR groups. by Kazuhiko Ikeuchi (9234268)

Subjects:

CCS1477 decreases phosphorylated ATR (pATR) and phosphorylated ATM (pATM). by Changkun Hu (12077989)

GO analysis of stage-salient genes in the order of decreasing significance (i.e, increasing p–value). by Sangeetha Muthamilselvan (8966006)

Proteins from the volcano plot which had notable increases or decreases listed in order of greatest to least magnitude of fold change and split by overall increase or overall decre... by Eiman Y. Ibrahim (10731078)

RDV and EIDD2801 EC₅₀ and fold-change in VeroE6-ACE2-TMPRSS2. by Agnieszka M. Szemiel (10196243)

Heatmap of fold-changes of metabolites. by Elena Heidenreich (6940475)

“…HL, i.e., 50 vs. 300 μmol photons m^-2 s^-1) for diploid (2N) and haploid (1N) <i>E</i>. …”

Positional cloning of <i>qNN1</i> on chromosome 16. by Xinxin Li (281237)

HA-MAD1 tumors have increased CIN and decreased p53. by Sarah E. Copeland (13951506)

* months from treatment initiation. by Kazuhiko Ikeuchi (9234268)

Subjects:

Association between the slope of the ratio of the post-treatment RPR titer compared to the baseline titer and other characteristics using linear regression analysis. by Kazuhiko Ikeuchi (9234268)

Subjects:

Temporal changes in the RPR titer from before to after treatment. by Kazuhiko Ikeuchi (9234268)

Subjects:

Flow chart of the study procedures. by Kazuhiko Ikeuchi (9234268)

Subjects:

The receiver operating characteristic curve (ROC) for using ucfDNA molecules with a size range of 130 to 160 bp within the DHSs to distinguish control subjects with hematuria from... by Meihui Chen (1670020)

Subjects:

Heatmap showing the end motifs of ucfDNA among different groups. by Meihui Chen (1670020)

Subjects:

Analysis of ucfDNA in DHSs between control and age-comparable bladder cancer groups. by Meihui Chen (1670020)

Subjects:

ROC analysis for differentiating bladder cancer patients from controls using the ucfDNA concentration before and after normalization by creatinine concentration in those samples wi... by Meihui Chen (1670020)

Subjects:

Size distributions of ucfDNA molecules. by Meihui Chen (1670020)

Subjects: